In contrast to China’s slow and secretive acknowledgement of SARS in 2003, the Chinese government and scientific community have been significantly more transparent regarding the coronavirus. On Jan. 31, Health and Human Services Secretary Alex Azar praised China for its “efforts and coordination with public health officials across the globe.” Advances ... READ MORE >
Life Sciences
The life sciences sector comprises some of the middle market’s fastest-growing companies. Whether developing life-saving new drugs or robotic components for surgery, this vibrant sector is a hotbed of innovation.
Want a fuller picture of biotech’s promise? Look beyond the public markets
A recent Wall Street Journal article highlights the underperformance of the Nasdaq Biotech Index against other benchmarks. The article implies the weak returns are due to a lack of blockbuster biotech therapies; at the same time, the piece underscores the robust private funding activity within the biotech ecosystem. The ecosystem and the capital markets in ... READ MORE >
Biotech needs cash in hesitant market
Life science companies require a cash infusion at least twice as big as that of 2018 to fund research and development at a time when investors remain skittish, according to a Bloomberg analysis. The analysis suggests that over 100 biotech companies, including makers of oncology therapies and treatments for other life-threatening conditions, need to raise ... READ MORE >
Better data use has pros and cons for life sciences
The volume and variety of health care data should expand significantly in 2019. Specifically, we will be monitoring growth in data sources outside those collected from traditional electronic health records, including information gleaned from wearable technology and direct-to-consumer genetic testing. Life science companies should consider how best to ... READ MORE >